Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 18/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19949834 | 0.93 | MAP4K1 (0.41) | MAP4K1NTRK1KITFLT3JAK3 | |
| SCHEMBL19949869 | 0.89 | MAP4K1 (0.45) | MAP4K1NTRK1KITFLT3FGFR1 | |
| SCHEMBL19949764 | 0.88 | MAP4K1 (0.46) | MAP4K1NTRK1KITFLT3JAK3 | |
| SCHEMBL19949830 | 0.83 | MAP4K1 (0.63) | MAP4K1NTRK1KITFLT3FGFR1 | |
| SCHEMBL19949930 | 0.82 | MAP4K1 (0.44) | MAP4K1NTRK1KITFLT3FGFR3 | |
| SCHEMBL19949915 | 0.81 | MAP4K1 (0.64) | MAP4K1NTRK1KITFLT3 | |
| SCHEMBL23962856 | 0.80 | MAP4K1 (0.38) | MAP4K1NTRK1KITFLT3FGFR1 | |
| SCHEMBL19964796 | 0.79 | MAP4K1 (0.42) | MAP4K1NTRK1KITFLT3FGFR3 | |
| SCHEMBL19949874 | 0.79 | NTRK1 (0.44) | MAP4K1NTRK1KITFLT3 | |
| SCHEMBL19949819 | 0.79 | MAP4K1 (0.47) | MAP4K1FLT3JAK3FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.